2.1.6 Transition from asymptomatic hyperuricemia to gout Only 10%20% of individuals with hyperuricemia develop gout, implicating critical roles for other regulatory factors (e.g., local tissue microenvironment and crystal-promoting factors) (Ohashi et al., 2024
Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management
Firstly, we isolated three distinct subpopulations based on their disparate ROS levels and observed significant upregulation of stemness genes, including CPT1A , in the ROS low or spheroid cells
Evening injections: sleeping through the worst of it The evening injection strategy follows a completely different logic
If you want to avoid the potential side effects, eating a balanced diet that contains a lot of glutathione appears to have no side effects whatsoever
Currently, there is a lack of long-term data on the safety of GLP-1 medications while pregnant